Earnings

Mirum Pharmaceuticals Raises FY2026 Sales Guidance from $680.000M-$700.000M to $715.000M-$720.000M vs $698.093M Est

Nov 3, 2026 · 04:29 PM ET· updated 42m ago

Mirum Pharmaceuticals (NASDAQ:MIRM) raises FY2026 sales outlook from $680.000 million-$700.000 million to $715.000 million-$720.000 million vs $698.093 million estimate.

Why It Matters

Mirum Pharmaceuticals now expects to earn more money next year than it thought before. When a company gets more confident about its future sales, it usually means their products are selling better than planned.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.

Tickers in Play

MIRM87.13

+1.39 (+1.62%)

MMM177.05

-1.31 (-0.73%)

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.